



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/723,590	11/25/2003	Dennis Triglia	VITA1120-1 7574		
75	90 03/07/2006	EXAMINER			
Lisa A. Haile, J.D., Ph.D.			CHEN, SHIN LIN		
GRAY CARY	WARE & FREIDENRIC				
Suite 1100			ART UNIT	PAPER NUMBER	
4365 Executive Drive			1632		
San Diego, CA	92121-2133	DATE MAILED: 03/07/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summany		Application N	on No. Applicant(s)					
		10/723,590		TRIGLIA ET AL.				
	Office Action Summary	Examiner		Art Unit				
		Shin-Lin Chen		1632				
Period fo	The MAILING DATE of this communication app or Reply	pears on the cov	er sheet with the co	orrespondence ad	ldress			
WHIC - Exter after - If NO - Failu Any r	CHEVER IS LONGER, FROM THE MAILING DANSION OF THE MAILING DANSIONS OF THE MAILING DANSIONS OF THE MAILING DANSIONS OF THE MAILING DANSION OF THE MAILING DANSION OF THE MAILING DANSION OF THE MAILING	ATE OF THIS (36(a). In no event, ho will apply and will expi e, cause the application	COMMUNICATION bwever, may a reply be time re SIX (6) MONTHS from to the to become ABANDONED	l. ely filed the mailing date of this co 0 (35 U.S.C. § 133).				
Status								
1)[]	Responsive to communication(s) filed on							
	This action is FINAL . 2b) This action is non-final.							
· · ·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims	•						
4)⊠	4)⊠ Claim(s) <u>1-28</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) is/are allowed.							
6)□	☐ Claim(s) is/are rejected.							
	☐ Claim(s) is/are objected to.							
8)⊠	8) Claim(s) 1-28 are subject to restriction and/or election requirement.							
Applicati	on Papers							
9) 🗌 :	The specification is objected to by the Examine	er.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	inder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).								
* 8	ee the attached detailed Office action for a list	of the certified	copies not received	d.				
Attachma=	Ve)							
Attachment	u(s) e of References Cited (PTO-892)	ى ⊏	Interview Summary (PTO 412)				
2) D Notice	e of Draftsperson's Patent Drawing Review (PTO-948)	4 1∟ -	Paper No(s)/Mail Dat	te				
3) 🔲 Infom	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date		Notice of Informal Pa	atent Application (PTC)-152)			

Art Unit: 1632

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-19 and 26, drawn to a C3A clonal cell line derived from a parental C3A cell line, wherein said clonal cell line has a doubling time in serum-free medium significantly less than that of said parent cell line, a method of making said cell line, and a method using said cell line to produce proteins, classified in class 435, subclasses 325 and 70.1.
 - II. Claims 20-25, drawn to a bio-artificial liver device comprising an apparatus containing the cells of claim 1, and a method of using said device for treating a subject having compromised liver function, classified in class 435, subclasses 395 and 400.
 - III. Claim 27, drawn to a method of screening compounds for metabolic activity by using the cells of claim 1, classified in class 435, subclasses 4,7.21 and 8.
 - IV. Claim 28, drawn to a method of studying enteric disease by using the cells of claim 1, classified in class 424, subclass 93.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different modes of operation and have different designs and functions.

Inventions I and II are drawn to compositions having different chemical structure, physical properties and functions, and require separate search: cell line vs. bio-artificial device. Search for cell line does not require search for device. Further, inventions I and

Application/Control Number: 10/723,590

Art Unit: 1632

II are distinct because they are drawn to materially different methods which differ at least in objectives, method steps, reagents and/or dosages used, schedules used, response variables, and criteria for success. Method of using cell lines to produce proteins *in vitro* requires different technical considerations and different modes of action from method of using device for treating a subject having compromised liver function. The differences between Inventions I and II are further underscored by their different classification and independent search status. Thus, they are not obvious variants and deemed patentably distinct.

Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different modes of operation and have different designs.

Inventions III and IV are distinct because they are drawn to materially different methods which differ at least in objectives, method steps, reagents and/or dosages used, schedules used, response variables, and criteria for success. Method of screening compounds for metabolic activity requires different technical considerations and different modes of action from method of studying enteric disease. The differences between Inventions III and IV are further underscored by their different classification and independent search status.

Thus, they are not obvious variants and deemed patentably distinct. Similarly, inventions IIII are patentably distinct from inventions III-IV because they are drawn to materially different methods which differ at least in objectives, method steps, reagents and/or dosages used, schedules used, response variables, and criteria for success.

Application/Control Number: 10/723,590

Art Unit: 1632

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (571) 272-0726. The examiner can normally be reached on Monday to Friday from 9:30 am to 6 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for this group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Art Unit: 1632

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Shin-Lin Chen, Ph.D.

SHIN-LIN CHEN
PRIMARY EXAMINER

Suhen